The Pharmacy Times® Neurology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Study: Patients with Pre-Symptomatic Spinal Muscular Atrophy Demonstrate Sustained Benefit from Nusinersen
After up to 4.8 years of treatment with nusinersen, 100% of children with spinal muscular atrophy (SMA) who were treated pre-symptomatically are still alive.
The researchers identified 87 articles using the PubMed and PsycINFO databases and the 2017 American Academy of Neurology (AAN) criteria for therapeutic trials.
Researchers Present Case Studies on Teriflunomide Therapy in Patients with COVID-19, Multiple Sclerosis
The authors posited that teriflunomide could prevent an excessive immune response while still maintaining enough defense against the virus.
SE requires prompt intervention to terminate seizure activity to prevent neuronal damage and complications.
Galcanezumab-gnlm (Emgality, Lilly) has received FDA-approval for the preventive treatment of migraine in adults and for the treatment of episodic cluster headache in adults.
As Alzheimer disease research evolves beyond targeting a single pathology, interventions should coordinate disease stage with pathology and the patient’s presenting characteristics.
According to a recent study, people with a higher risk of cardiovascular disease demonstrate an increase in cognitive decline, including a rise in the typical markers of Alzheimer disease.
New treatment options offer hopes of better clinical outcomes for patients suffering from Parkinson disease and its debilitating daily symptoms.
Dihydroergotamine Mesylate Nasal Spray is FDA-approved as therapeutic equivalent to Migranal.
Telemedicine and connected devices are emerging as technologies to provide greater access and convenience to care for those who can defer treatment by way of an in-person consultation.
The recommended dosage of lemborexant CIV is one 5 mg tablet taken no more than once per night, immediately before going to bed with at least 7 hours remaining before the planned time of awakening.
Ensuring patients continue receiving life-sustaining home infusions that were traditionally administered in the hospital or hospital clinic settings is of the upmost importance.